Tilray Brands (NASDAQ:TLRY) Deepens Its Medical Cannabis Reach
Tilray Brands advances international medical cannabis access while regulatory progress, beverages, wellness brands, and operational discipline shape its evolving business outlook.
Should you buy Tilray Brands stock before July 28?
Tilray will release its year-end numbers next week, which could have a significant impact on the stock.
ACB stock down 28% in three months: Time to buy the dip or cash out?
Shares of Aurora Cannabis ACB have lost 27% over the past three months, despite the cannabis operator delivering better-than-expected fourth-quarter 2026 (year ended March 2026) revenues and earnings.
Why Is Aurora Cannabis (NASDAQ:ACB) Back In Focus?
Aurora Cannabis gains attention after fresh recognition highlights its medical cannabis operations, product quality, compliance, and global reach.
MSOS: Adult-Use Rescheduling The Next Catalyst For Cannabis Stocks
The AdvisorShares Pure US Cannabis ETF is rated a buy, driven by real regulatory progress and potential further catalysts. Click here to read more on MSOS.
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Why Is Trulieve Cannabis (NYSE:TRLV) Watching NYSE Composite?
Explore Trulieve Cannabis (NYSE:TRLV), operating across regulated cannabis markets, with insights into business operations, Florida presence, and the company’s role within the NYSE Composite.
Is Canopy Growth stock finally worth buying after losing 99% of its value?
A lower stock price doesn’t eliminate investment risk.
Tilray’s stock is down over 50% this year. Has it become a bargain buy?
The cannabis stock recently hit a new 52-week low.
Is Green Thumb stock oversold? The case for 100% upside.
It’s a rare gem among marijuana stocks, for several reasons.
The Easiest Way to Bet on US Cannabis Is This One ETF
One ETF promises investors a clean shot at the U.S. cannabis trade, but the inside of this fund is stranger than its simple ticker suggests.
DEA Rescheduling Hearing Puts Cannabis Stocks in Focus Ahead of a July 15 Deadline
The DEA’s cannabis rescheduling hearing runs through a July 15 deadline, putting cannabis stocks and the MSOS ETF in focus.
Innovative Industrial Properties: Cannabis Rescheduling Progress Reinforces The Re-Rating Thesis
Innovative Industrial’s AFFO was stable at $1.88/share, and leverage is still low for a REIT. Click here to read why IIPR stock is a Strong Buy.
3 reasons to buy Green Thumb Industries stock hand over fist
Green Thumb continues to execute while competitors struggle.
Trulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in One Year
This vertically integrated cannabis operator reported significant insider selling in its latest SEC disclosure.
Recent Comments